Company profile: Selux Diagnostics
1.1 - Company Overview
Company description
- Provider of next-generation phenotyping solutions for rapid antimicrobial susceptibility testing (AST). Offers the Selux NGP System, proprietary 384-well panels delivering exact MICs across a wide range of antibiotics, the Selux Separator and Inoculator for automated sample preparation from positive blood cultures, and Selux Site Software to streamline workflow and deliver actionable AST results.
Products and services
- Selux Panels: Laboratory-grade proprietary 384-well panels for AST, capable of testing against a wide range of antibiotics and producing exact MICs to guide personalized antimicrobial treatment
- Next Generation Phenotyping (NGP) System: A custom-engineered system performing rapid antimicrobial susceptibility testing across all sample types, utilizing a proprietary 384-well panel to enable comprehensive testing for personalized antimicrobial therapies
- Selux Site Software: Modular software that integrates with the Selux NGP System to streamline workflow, supplies clear instructions for sample preparation, and delivers actionable AST results
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Selux Diagnostics
Ibis Biosciences
HQ: United States
Website
- Description: Provider of products for the identification and characterization of infectious agents, including the Ibis T5000 Biosensor System, a hardware platform that identifies biological organisms such as bacteria, viruses, fungi and protozoa and provides information on drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ibis Biosciences company profile →
Revelation Biosciences
HQ: United States
Website
- Description: Provider of immunologic therapeutics and diagnostics, including Gemini, a proprietary PHAD formulation for systemic administration for prevention of post-surgical infection, acute kidney injury, and chronic kidney disease; GEM-AKI and GEM-CKD therapies that redirect the innate immune response; and GEM-SSI for prevention or treatment of healthcare-associated bacterial infections (post-surgical/post-burn, UTIs, sepsis, antibiotic-resistant).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revelation Biosciences company profile →
ContraFect
HQ: United States
Website
- Description: Provider of biotechnology research focused on monoclonal antibodies to treat life-threatening infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ContraFect company profile →
Melinta
HQ: United States
Website
- Description: Provider of antibiotics, developing and commercializing antibiotics to overcome drug-resistant infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Melinta company profile →
Mesa Biotech
HQ: United States
Website
- Description: Provider of DNA and RNA molecular testing services and COVID-19 diagnostic products, including the Accula SARS-CoV-2 molecular test and testing kits with high-throughput and rapid tests, controls, combo kits, reagents, and buffers. Based in San Diego, California, with a satellite testing laboratory in Santa Fe, New Mexico.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mesa Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Selux Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Selux Diagnostics
2.2 - Growth funds investing in similar companies to Selux Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Selux Diagnostics
4.2 - Public trading comparable groups for Selux Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →